Cardiac Channelopathies: Clinical Diagnosis and Promising Therapeutics

Authors, Journal, Affiliations, Type, DOI

• Ryan Dib Nehme, Lilas Sinno, Wael Shouman, Joanna A. Ziade, Lama A. Ammar, Ghadir Amin, George W. Booz, Fouad A. Zouein
• Journal of the American Heart Association (JAHA), 2025
• Department of Pharmacology and Toxicology, American University of Beirut Faculty of Medicine; University of Mississippi Medical Center
• Contemporary Review
• DOI: https://doi.org/10.1161/JAHA.124.040072

Overview

This contemporary review covers the six major cardiac channelopathies — LQTS, SQTS, Brugada syndrome, early repolarization syndrome, CPVT, and IVF — which are inherited primary electrical disorders of the heart without structural defects. Together they account for >50% of sudden cardiac death (SCD) in individuals under 50. The paper reviews the molecular and genetic mechanisms, diagnostic approaches (including scoring systems and genetic testing), and management strategies for each condition. Emerging therapeutics — including iPSC models, CRISPR/Cas9, RNA-based therapy, and AI diagnostics — are also discussed.

Keywords

cardiac electrophysiology, channelopathies, heart rhythm disorders, inherited arrhythmias, sudden cardiac death

Key Takeaways

Long QT Syndrome (LQTS)

• Most prevalent channelopathy (~1:2500 prospective estimate; possibly 1:2000 accounting for silent carriers); 17 genetic subtypes defined
• Top three genes: KCNQ1 (LQT1, 30–35%), KCNH2 (LQT2, 25–30%), SCN5A (LQT3, 5–10%); KCNQ1/KCNH2 = loss-of-function (reduced K⁺ repolarisation); SCN5A = gain-of-function (persistent Na⁺ influx)
• Rare but severe subtypes: Timothy syndrome (LQT8, CACNA1C gain-of-function), Jervell and Lange-Nielsen syndrome (KCNQ1/KCNE1 homozygous, associated with sensorineural deafness), Andersen-Tawil syndrome (LQT7, KCNJ2 — triad of arrhythmia, periodic paralysis, dysmorphic features)
• Arrhythmic risk peaks in childhood and decreases over time; males aged 10–12 have 4× higher relative risk; females aged 18–40 carry higher absolute risk (11% vs 2%) due to estrogen inhibiting IKr; postpartum period is highest-risk phase for women
• Schwartz Score used to assess probability: ≤1 = low; >1–3 = intermediate; ≥3.5 = high
• Management: nadolol is preferred non-selective β-blocker; LCSD for β-blocker failures (post-LCSD QTc <500 ms predicts success); mexiletine for LQT3; ICD for aborted arrest or refractory cases; lumacaftor trial for LQT2 ongoing (NCT04581408)
• Variant location within the gene matters: pore-region KCNH2 variants carry the greatest relative risk of cardiac events

Short QT Syndrome (SQTS)

• Prevalence 0.02–0.1% in adults; autosomal dominant with low penetrance; male predominance
• SQT1–3: gain-of-function in K⁺ channel genes (KCNH2, KCNQ1, KCNJ2); SQT4–6: loss-of-function in L-type Ca²⁺ channel subunits (CACNA1C, CACNB2, CACNA2D1); SQT7: SCN5A R689H loss-of-function; SQT8: SLC4A3 loss-of-function (Cl⁻/HCO₃⁻ exchanger)
• Diagnosed when QTc <340 ms, or QTc 320–360 ms with arrhythmic syncope; Schwartz SQTS score (≤2 = low; 3 = intermediate; ≥4 = high)
• ICD is first-line for symptomatic patients; quinidine (hydroquinidine) is first-line pharmacotherapy — prolongs AP by multichannel blockade
• Amiodarone and sotalol ineffective in SQTS1 despite being IKr blockers — ion channel mutations alter drug-channel gating properties

Brugada Syndrome (BrS)

• Prevalence 3–5/10,000; 8–10× more common in males; ~2/3 of patients are asymptomatic; SCD is first presentation in some
• Responsible for 4–12% of all SCD; up to 28% of SCD in structurally normal hearts
• SCN5A loss-of-function is the only definitive causative gene (15–30% of cases); >250 pathogenic variants across >27 genes (Table 4 in source); SCN5A-positive cases have more severe phenotype
• Pathophysiology remains controversial: repolarisation hypothesis (outward current shift in RV epicardium → phase 2 reentry) vs. depolarisation hypothesis (fibrosis + reduced Nav1.5/Cx43 → slow conduction in RVOT) vs. neural crest theory
• Type 1 (coved) ECG: J-point ≥2 mm, descending ST, negative T wave in V1–V2 — is diagnostic; Type 2/3 (saddleback) are not diagnostic alone; sodium channel blockers (ajmaline, flecainide) can unmask Type 1
• Shanghai Score: <2 = nondiagnostic; 2–3 = possible BrS; ≥3.5 = probable/definite BrS
• Management: ICD for symptomatic patients; quinidine/hydroquinidine for ICD-ineligible or recurrent shocks; IV isoproterenol for electrical storms; radiofrequency ablation for refractory cases (normalises ECG and prevents VT/VF inducibility)
• BrAID trial (NCT04641585): machine learning + transcriptomics platform for Type 1 BrS diagnosis; RNA-based therapies under investigation

Early Repolarization Syndrome (ERS)

• Previously considered benign; now linked to SCD risk; prevalence ~5.8% adults (up to 33.9% in athletes); more common in Black and Southeast Asian individuals
• Most studied gene: KCNJ8 gain-of-function (Kir6.1 subunit of KATP channel); ABCC9 also linked; CACNA1C, CACNB2, CACNA2D1 loss-of-function account for ~16% of probands
• Shanghai Score for ERS: <3 = nondiagnostic; 3–4.5 = possible ERS; ≥5 = probable/definite ERS
• Asymptomatic ERP: no treatment required; symptomatic/high-risk ERP: ICD; pharmacotherapy with quinidine (inhibits Ito), PDE-III inhibitors (cilostazol, milrinone — reduce Ito, augment ICa), isoproterenol (restores epicardial AP dome)
• ARumenamide-787 (experimental): inhibits Ito, enhances INa — suppressed J wave and prevented arrhythmias in canine BrS/ERS models; VF Mapping trial (NCT03764592) assessing electrocardiographic imaging for substrate-guided ablation

Catecholaminergic Polymorphic VT (CPVT)

• Prevalence ~1:10,000; one of the most common causes of SCD in individuals <35 with structurally normal hearts; responsible for ~15% of SCD in youth; up to 50% mortality by age 35 if unrecognised
• Average symptom onset age 7–12 years; 60% have first syncope by age 20; often misdiagnosed as epilepsy or vasovagal syncope
• RYR2 gain-of-function (CPVT1): 60–70% of cases — excessive SR Ca²⁺ release during diastole → delayed afterdepolarizations → bidirectional or polymorphic VT on exertion/stress
• CASQ2 loss-of-function (CPVT2): 2–5% of cases, autosomal recessive; more severe phenotype in homozygotes; CASQ2 regulates Ca²⁺ buffering and RYR2 activity; CASQ2-targeted AAV gene therapy under active investigation
• Diagnosis: exercise stress test (provokes VT in ~2/3); "burst" exercise protocol for equivocal cases; epinephrine infusion if exercise testing not feasible; Holter less sensitive; genetic testing recommended by HRS/EHRA for all clinically suspected CPVT
• ECG hallmarks: bidirectional VT (180° QRS alternation), late-coupled PVCs — left bundle branch block pattern with inferior axis is most specific (suggests RVOT ectopic focus)
• Management: non-selective β-blockers cornerstone (nadolol preferred); flecainide added for refractory cases; LCSD (thoracoscopic lower 2/3 left stellate ganglion + upper thoracic ganglia) effective in pharmacologically refractory CPVT; ICD as last resort (ICD shocks can provoke catecholaminergic surge and worsen arrhythmia); CRISPR/Cas9 and CASQ2 gene therapy in development

Idiopathic Ventricular Fibrillation (IVF)

• Diagnosis of exclusion following documented VF with resuscitated cardiac arrest, after ruling out structural disease, ion channel disorders, and cardiomyopathies
• Mechanism: short-coupled Purkinje-derived PVCs descending on T wave (R-on-T phenomenon)
• Relevant genes: CALM1, RYR2, IRX family transcription factors, DPP6 (chromosome 7 haplotype elevated >20× in IVF vs controls — potential diagnostic biomarker)
• No strict diagnostic workup exists; minimum workup recommended includes CMR, exercise treadmill test, and sodium channel blocker provocation
• Treatment: ICD; acute electrical storm — IV isoproterenol, verapamil, or quinidine; chronic suppression with quinidine; catheter ablation of triggering PVC focus for refractory cases
• Ongoing trials: quinidine/verapamil pilot (NCT05593757, Amsterdam); electrophysiological mapping of IVF substrate (NCT03963271, Maastricht)

Conclusions

• Channelopathies cause >50% of SCD in individuals aged <50 years; SCD kills 250,000–300,000 Americans annually
• Scoring systems (Schwartz for LQTS/SQTS; Shanghai Score for BrS/ERS) standardise diagnosis alongside 12-lead ECG, genetic testing, and electrophysiological studies
• iPSC-derived cardiomyocytes, CRISPR/Cas9, in silico modelling, and high-throughput automated patch clamp assays are enabling precision medicine and variant-specific drug testing
• Genotype-guided pharmacotherapy is increasingly important: drug response can differ substantially by mutation (e.g., mexiletine for LQT3; amiodarone ineffective in SQTS1)

Key Concepts Mentioned

• concepts/Cardiac-Action-Potential — basis for understanding how ion channel mutations produce arrhythmias
• concepts/Ion-Channel-Mutations — gain- and loss-of-function mutations underlying all six channelopathies
• concepts/Sudden-Cardiac-Death — primary outcome these channelopathies cause
• concepts/Torsades-de-Pointes — polymorphic VT pattern characteristic of LQTS
• concepts/Bidirectional-Ventricular-Tachycardia — hallmark arrhythmia of CPVT
• concepts/Schwartz-Score — diagnostic scoring for LQTS and SQTS
• concepts/Shanghai-Score-System — diagnostic scoring for BrS and ERS
• concepts/Left-Cardiac-Sympathetic-Denervation — surgical intervention for LQTS and CPVT; thoracoscopic lower 2/3 left stellate ganglion resection
• concepts/iPSC-Derived-Cardiomyocytes — disease modeling and drug testing platform
• concepts/CRISPR-Cas9-in-Channelopathies — gene editing application for LQTS and CPVT
• concepts/Sex-Differences-in-Channelopathies — estrogen inhibits IKr (prolongs QT); testosterone reduces QT; postpartum is peak risk period for LQTS women; males aged 10–12 have 4× higher arrhythmic risk

Key Entities Mentioned

• entities/Long-QT-Syndrome — most prevalent channelopathy; 17 subtypes; detailed treatment algorithm
• entities/Short-QT-Syndrome — rare; male-predominant; quinidine first-line
• entities/Brugada-Syndrome — SCN5A-driven; type 1 ECG diagnostic; BrAID AI trial underway
• entities/Early-Repolarization-Syndrome — formerly benign; now linked to SCD risk
• entities/CPVT — exercise-triggered; RYR2 mutations predominate; LCSD for refractory cases
• entities/Idiopathic-Ventricular-Fibrillation — exclusionary diagnosis; DPP6 biomarker
• entities/SCN5A — key gene for BrS (loss-of-function), LQT3 (gain-of-function), IVF, ERS; most causative single gene for BrS
• entities/RYR2 — predominant CPVT gene (CPVT1, 60–70%); ryanodine receptor 2; gain-of-function → excess SR Ca²⁺ release → delayed afterdepolarizations
• entities/CASQ2 — second most common CPVT gene (2–5%); loss-of-function; autosomal recessive; regulates Ca²⁺ buffering and RYR2; target of active AAV gene therapy
• entities/KCNQ1 — LQT1 gene (loss-of-function, 30–35%); slow delayed rectifier IKs; also gain-of-function → SQTS2; homozygous → Jervell and Lange-Nielsen syndrome
• entities/KCNH2 — LQT2 gene (loss-of-function, 25–30%); IKr rapid delayed rectifier; pore-region variants carry highest event risk; gain-of-function → SQTS1
• entities/KCNJ2 — LQT7 (Andersen-Tawil syndrome, loss-of-function); also SQTS3 and minor CPVT gene; encodes Kir2.1 inward rectifier
• entities/CACNA1C — LQT8 (Timothy syndrome, gain-of-function); loss-of-function in BrS (6.6%), ERS (4.1%), SQTS4; encodes Cav1.2 L-type calcium channel α-subunit
• entities/CALM1 — LQT14 and CPVT (calmodulinopathy); gain-of-function → abnormal calcium signalling; autosomal sporadic/dominant

Limitations of the Document

• The link between specific genetic mutations and SCD risk remains incompletely understood; genotype-phenotype associations are not fully established for several subtypes
• BrS pathophysiology remains controversial: depolarization vs. repolarization hypothesis vs. neural crest theory
• IVF has no strict diagnostic workup; guideline recommendations are general
• Amiodarone and sotalol are ineffective in SQTS1 despite being IKr blockers — ion channel mutations appear to alter drug-channel interactions
• Risk stratification in asymptomatic BrS and ERS patients remains an open clinical challenge

Wiki Pages Updated

• wiki/index.md (created)
• wiki/log.md (updated)
• wiki/sources/channelopathies-jaha-2025.md (created; improved 2026-04-18)
• wiki/concepts/Cardiac-Action-Potential.md (created)
• wiki/concepts/Ion-Channel-Mutations.md (created)
• wiki/concepts/Sudden-Cardiac-Death.md (created)
• wiki/concepts/Torsades-de-Pointes.md (created)
• wiki/concepts/Bidirectional-Ventricular-Tachycardia.md (created)
• wiki/concepts/Schwartz-Score.md (created)
• wiki/concepts/Shanghai-Score-System.md (created)
• wiki/concepts/Left-Cardiac-Sympathetic-Denervation.md (created)
• wiki/concepts/iPSC-Derived-Cardiomyocytes.md (created)
• wiki/concepts/CRISPR-Cas9-in-Channelopathies.md (created)
• wiki/concepts/Sex-Differences-in-Channelopathies.md (created)
• wiki/entities/Long-QT-Syndrome.md (created)
• wiki/entities/Short-QT-Syndrome.md (created)
• wiki/entities/Brugada-Syndrome.md (created)
• wiki/entities/Early-Repolarization-Syndrome.md (created)
• wiki/entities/CPVT.md (created)
• wiki/entities/Idiopathic-Ventricular-Fibrillation.md (created)
• wiki/entities/SCN5A.md (created)
• wiki/entities/RYR2.md (created)
• wiki/entities/CASQ2.md (created)
• wiki/entities/KCNQ1.md (created)
• wiki/entities/KCNH2.md (created)
• wiki/entities/KCNJ2.md (created)
• wiki/entities/CACNA1C.md (created)
• wiki/entities/CALM1.md (created)